Mieke Van Hemelrijck

List of Publications by Year
in descending order

325 papers	7,688 citations	50170 46 h-index	85405 71 g-index
334 all docs	334 docs citations	334 times ranked	12519 citing authors

#	Article	IF	Citations
1	Associations between immune-suppressive and stimulating drugs and novel COVID-19â€"a systematic review of current evidence. Ecancermedicalscience, 2020, 14, 1022.	0.6	360
2	COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?. Ecancermedicalscience, 2020, 14, 1023.	0.6	235
3	Risk and Timing of Cardiovascular Disease After Androgen-Deprivation Therapy in Men With Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 1243-1251.	0.8	225
4	Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis. European Urology, 2015, 68, 386-396.	0.9	211
5	Blood Pressure and Risk of Cancer Incidence and Mortality in the Metabolic Syndrome and Cancer Project. Hypertension, 2012, 59, 802-810.	1.3	210
6	Cohort Profile: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. International Journal of Epidemiology, 2013, 42, 956-967.	0.9	194
7	Absolute and Relative Risk of Cardiovascular Disease in Men With Prostate Cancer: Results From the Population-Based PCBaSe Sweden. Journal of Clinical Oncology, 2010, 28, 3448-3456.	0.8	173
8	The global prevalence of erectile dysfunction: a review. BJU International, 2019, 124, 587-599.	1.3	170
9	Global incidence and outcome of testicular cancer. Clinical Epidemiology, 2013, 5, 417.	1.5	138
10	Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncology, The, 2010, 11, 450-458.	5.1	110
11	Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Translational Andrology and Urology, 2018, 7, 83-97.	0.6	99
12	Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer Cell, 2021, 39, 257-275.e6.	7.7	93
13	Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nature Communications, 2017, 8, 420.	5.8	91
14	Anosmia and ageusia are emerging as symptoms in patients with COVID-19: What does the current evidence say?. Ecancermedicalscience, 2020, 14, ed98.	0.6	88
15	Prostate cancer risk in the Swedish AMORIS study. Cancer, 2011, 117, 2086-2095.	2.0	87
16	Risk of inâ€hospital complications after radical cystectomy for urinary bladder carcinoma: populationâ€based followâ€up study of 7608 patients. BJU International, 2013, 112, 1113-1120.	1.3	84
17	Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons â€" the Swedish AMORIS study. European Journal of Cancer, 2011, 47, 2033-2041.	1.3	83
18	Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. European Urology, 2018, 74, 261-280.	0.9	82

#	Article	IF	Citations
19	Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL). European Urology, 2020, 77, 110-118.	0.9	82
20	Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Baseâ€"a refined prostate cancer trajectory. International Journal of Epidemiology, 2016, 45, 73-82.	0.9	78
21	Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE. Oncogene, 2016, 35, 5155-5169.	2.6	76
22	Serum Lipid Profiles and Cancer Risk in the Context of Obesity: Four Meta-Analyses. Journal of Cancer Epidemiology, 2013, 2013, 1-12.	0.5	73
23	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncology, The, 2021, 22, 1669-1680.	5.1	73
24	Lipid Profiles and Risk of Breast and Ovarian Cancer in the Swedish AMORIS Study. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1381-1384.	1.1	72
25	Systematic review of high-intensity focused ultrasound ablation in the treatment of breast cancer. British Journal of Surgery, 2015, 102, 873-882.	0.1	70
26	Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study. Journal of Cancer Epidemiology, 2012, 2012, 1-10.	0.5	67
27	A Systematic Review and Meta-analysis of Delay in Radical Cystectomy and the Effect on Survival in Bladder Cancer Patients. European Urology Oncology, 2020, 3, 239-249.	2.6	67
28	Quantifying the Evidence for the Risk of Metabolic Syndrome and Its Components following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis. PLoS ONE, 2015, 10, e0117344.	1.1	67
29	Serum lactate dehydrogenase and survival following cancer diagnosis. British Journal of Cancer, 2015, 113, 1389-1396.	2.9	66
30	Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes and Control, 2011, 22, 1011-1019.	0.8	63
31	Inorganic phosphate and the risk of cancer in the Swedish AMORIS study. BMC Cancer, 2013, 13, 257.	1.1	62
32	Serum inflammatory markers and colorectal cancer risk and survival. British Journal of Cancer, 2017, 116, 1358-1365.	2.9	61
33	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. European Urology, 2019, 75, 523-531.	0.9	58
34	Calcium Intake and Serum Concentration in Relation to Risk of Cardiovascular Death in NHANES III. PLoS ONE, 2013, 8, e61037.	1.1	57
35	Is there a role for <scp>IGF</scp>â€1 in the development of second primary cancers?. Cancer Medicine, 2016, 5, 3353-3367.	1.3	57
36	Association between serum calcium concentration and risk of incident and fatal cardiovascular disease in the prospective AMORIS study. Atherosclerosis, 2016, 251, 85-93.	0.4	56

#	Article	IF	Citations
37	Determinants of cancer screening awareness and participation among Indonesian women. BMC Cancer, 2018, 18, 208.	1.1	55
38	Adjuvant taxanes and the development of breast cancer-related arm lymphoedema. British Journal of Surgery, 2015, 102, 1071-1078.	0.1	54
39	Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. OncoImmunology, 2015, 4, e1032492.	2.1	53
40	Association between Levels of C-Reactive Protein and Leukocytes and Cancer: Three Repeated Measurements in the Swedish AMORIS Study. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 428-437.	1.1	52
41	Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma. British Journal of Surgery, 2018, 105, 1639-1649.	0.1	52
42	Iron metabolism and risk of cancer in the Swedish AMORIS study. Cancer Causes and Control, 2013, 24, 1393-1402.	0.8	51
43	The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. BJU International, 2018, 121, 737-744.	1.3	51
44	Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU International, 2011, 108, 1279-1283.	1.3	50
45	Depression, anxiety, and suicidality in patients with prostate cancer: a systematic review and meta-analysis of observational studies. Prostate Cancer and Prostatic Diseases, 2021, 24, 281-289.	2.0	50
46	Time-Dependent COVID-19 Mortality in Patients With Cancer. JAMA Oncology, 2022, 8, 114.	3.4	50
47	Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. Cancer Causes and Control, 2010, 21, 1657-1667.	0.8	49
48	Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London. Frontiers in Oncology, 2020, 10, 1279.	1.3	49
49	The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study. International Journal of Cancer, 2012, 130, 2118-2128.	2.3	47
50	Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. International Journal of Cancer, 2017, 140, 611-617.	2.3	47
51	Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories. Cancer Medicine, 2016, 5, 1307-1318.	1.3	46
52	Systematic review of radioguided versus wire-guided localization in the treatment of non-palpable breast cancers. Breast Cancer Research and Treatment, 2013, 140, 241-252.	1.1	44
53	Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer. Clinical Cancer Research, 2018, 24, 1617-1628.	3.2	44
54	Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients. Carcinogenesis, 2015, 36, 1121-1128.	1.3	43

#	Article	IF	Citations
55	Causes of death in men with localized prostate cancer: a nationwide, populationâ€based study. BJU International, 2016, 117, 507-514.	1.3	43
56	Risk of COVID-19 death in cancer patients: an analysis from Guyâ€™s Cancer Centre and Kingâ€™s College Hospital in London. British Journal of Cancer, 2021, 125, 939-947.	2.9	41
57	Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study. International Journal of Cancer, 2018, 142, 2254-2262.	2.3	40
58	Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 4290-4304.	0.4	40
59	Risk of prostate cancer is not associated with levels of Câ€reactive protein and other commonly used markers of inflammation. International Journal of Cancer, 2011, 129, 1485-1492.	2.3	39
60	COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. Cancers, 2021, 13, 3573.	1.7	39
61	Thromboembolic Events Following Surgery for Prostate Cancer. European Urology, 2013, 63, 354-363.	0.9	38
62	Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study. Oncotarget, 2017, 8, 42332-42342.	0.8	37
63	Impact of age on the toxicity of immune checkpoint inhibition. , 2020, 8, e000871.		37
64	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. European Journal of Cancer, 2021, 150, 190-202.	1.3	37
65	Cohort Profile: The AMORIS cohort. International Journal of Epidemiology, 2017, 46, 1103-1103i.	0.9	35
66	Barriers and facilitators to physical activity in men with prostate cancer: A qualitative and quantitative systematic review. Psycho-Oncology, 2019, 28, 2270-2285.	1.0	35
67	Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases. Oncogene, 2020, 39, 3666-3679.	2.6	35
68	Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival. OncoImmunology, 2016, 5, e1154250.	2.1	34
69	Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19. JAMA Network Open, 2022, 5, e220130.	2.8	34
70	Comparison of three magnetic nanoparticle tracers for sentinel lymph node biopsy in an in vivo porcine model. International Journal of Nanomedicine, 2015, 10, 1235.	3.3	33
71	Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. Breast Cancer Research and Treatment, 2018, 172, 167-177.	1.1	33
72	CanWalk: a feasibility study with embedded randomised controlled trial pilot of a walking intervention for people with recurrent or metastatic cancer. BMJ Open, 2017, 7, e013719.	0.8	31

#	Article	IF	Citations
73	Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study. BMC Cancer, 2019, 19, 858.	1.1	30
74	Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. European Urology, 2019, 76, 258-259.	0.9	30
75	Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. International Journal of Cancer, 2016, 139, 2698-2704.	2.3	29
76	Serum Calcium and the Risk of Breast Cancer: Findings from the Swedish AMORIS Study and a Meta-Analysis of Prospective Studies. International Journal of Molecular Sciences, 2016, 17, 1487.	1.8	28
77	The incidence and prevalence of upper tract urothelial carcinoma: a systematic review. BMC Urology, 2021, 21, 110.	0.6	28
78	Incidence of Second Malignancies for Prostate Cancer. PLoS ONE, 2014, 9, e102596.	1.1	27
79	Association Between Vitamin D and Novel SARS-CoV-2 Respiratory Dysfunction â€“ A Scoping Review of Current Evidence and Its Implication for COVID-19 Pandemic. Frontiers in Physiology, 2020, 11, 564387.	1.3	27
80	Serum calcium and risk of gastrointestinal cancer in the Swedish AMORIS study. BMC Public Health, 2013, 13, 663.	1.2	26
81	Serum leptin, Câ€reactive protein, and cancer mortality in the <scp>NHANES III</scp>. Cancer Medicine, 2016, 5, 120-128.	1.3	26
82	Androgen deprivation therapy for prostate cancer and risk of dementia. BJU International, 2019, 124, 87-92.	1.3	26
83	Primary cancers before and after prostate cancer diagnosis. Cancer, 2012, 118, 6207-6216.	2.0	25
84	Cognitive training for technical and nonâ€technical skills in robotic surgery: a randomised controlled trial. BJU International, 2018, 122, 1075-1081.	1.3	25
85	Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer: results from a prospective non-randomised trial. British Journal of Sports Medicine, 2022, 56, 402-409.	3.1	25
86	Family history of breast cancer and its association with disease severity and mortality. Cancer Medicine, 2016, 5, 942-949.	1.3	24
87	Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 664.e11-664.e18.	0.8	24
88	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance Initiative. European Urology Oncology, 2020, 3, 80-91.	2.6	24
89	Biomarker-based score to predict mortality in persons aged 50 years and older: a new approach in the Swedish AMORIS study. International Journal of Molecular Epidemiology and Genetics, 2012, 3, 66-76.	0.4	24
90	Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy. BJU International, 2016, 118, 391-398.	1.3	23

#	Article	IF	Citations
91	Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis. BMC Cancer, 2015, 15, 913.	1.1	22
92	Unmet needs in sexual health in bladder cancer patients: a systematic review of the evidence. BMC Urology, 2020, 20, 64.	0.6	22
93	Serum calcium and incident and fatal prostate cancer in the Swedish AMORIS study. Cancer Causes and Control, 2012, 23, 1349-1358.	0.8	21
94	Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden. International Journal of Cancer, 2012, 130, 478-487.	2.3	21
95	Mortality following Hip Fracture in Men with Prostate Cancer. PLoS ONE, 2013, 8, e74492.	1.1	21
96	Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study. European Urology, 2017, 72, 920-928.	0.9	21
97	The effectiveness of the Guyâ€™s Rapid Diagnostic Clinic (RDC) in detecting cancer and serious conditions in vague symptom patients. British Journal of Cancer, 2021, 124, 1079-1087.	2.9	21
98	Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial. European Urology, 2022, 81, 385-393.	0.9	21
99	Serum Glucose and Fructosamine in Relation to Risk of Cancer. PLoS ONE, 2013, 8, e54944.	1.1	20
100	Impact of incremental circumferential resection margin distance on overall survival and recurrence in oesophageal adenocarcinoma. BJS Open, 2018, 2, 229-237.	0.7	20
101	Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma. OncoImmunology, 2019, 8, e1593811.	2.1	20
102	Metabolic syndrome biomarkers and prostate cancer risk in the <scp>UK</scp> Biobank. International Journal of Cancer, 2021, 148, 825-834.	2.3	20
103	Cancer and COVID-19 vaccines: a complex global picture. Lancet Oncology, The, 2021, 22, 749-751.	5.1	20
104	Preâ€diabetes and serum sex steroid hormones among <scp>US</scp> men. Andrology, 2017, 5, 49-57.	1.9	19
105	A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitus. Ecancermedicalscience, 2018, 12, 802.	0.6	19
106	PCASTt/SPCG-17â€”a randomised trial of active surveillance in prostate cancer: rationale and design. BMJ Open, 2019, 9, e027860.	0.8	19
107	Investigating the impact of open label design on patientâ€reported outcome results in prostate cancer randomized controlled trials. Cancer Medicine, 2020, 9, 7363-7374.	1.3	19
108	Risk of cardiovascular disease following gonadotropinâ€releasing hormone agonists vs antagonists in prostate cancer: Realâ€world evidence from five databases. International Journal of Cancer, 2021, 148, 2203-2211.	2.3	19

#	Article	IF	Citations
109	Heterocyclic Aromatic Amine [HCA] Intake and Prostate Cancer Risk: Effect Modification by Genetic Variants. Nutrition and Cancer, 2012, 64, 704-713.	0.9	18
110	Magnetic sentinel lymph node biopsy and localization properties of a magnetic tracer in an in vivo porcine model. Breast Cancer Research and Treatment, 2013, 141, 33-42.	1.1	18
111	Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time. British Journal of Cancer, 2016, 114, 88-95.	2.9	18
112	Patterns of recurrence in oesophageal cancer following oesophagectomy in the era of neoadjuvant chemotherapy. BJS Open, 2017, 1, 182-190.	0.7	18
113	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. European Urology, 2019, 76, 693-702.	0.9	18
114	Introducing PIONEER: a project to harness big data in prostate cancer research. Nature Reviews Urology, 2020, 17, 351-362.	1.9	18
115	Simulation in Urological Training and Education (SIMULATE): Protocol and curriculum development of the firstÂmulticentre international randomized controlled trial assessing the transferability of simulationâ€based surgicalÂtraining. BJU International, 2020, 126, 202-211.	1.3	18
116	Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer. European Urology, 2017, 72, 534-541.	0.9	17
117	Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer. BMC Cancer, 2017, 17, 494.	1.1	17
118	The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 309.e15-309.e23.	0.8	17
119	Continuity of Cancer Care: The Surgical Experience of Two Large Cancer Hubs in London and Milan. Cancers, 2021, 13, 1597.	1.7	17
120	Prostate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested?. BMJ Open, 2016, 6, e011356.	0.8	16
121	Who is at risk of death from nephrectomy? An analysis of thirtyâ€day mortality after 21 380 nephrectomies in 3 years of the British Association of Urological Surgeons (BAUS) National Nephrectomy Audit. BJU International, 2017, 120, 358-364.	1.3	16
122	Investigating nutrition and lifestyle factors as determinants of abdominal obesity: an environment-wide study. International Journal of Obesity, 2017, 41, 340-347.	1.6	16
123	Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results. JAMA Network Open, 2019, 2, e1914689.	2.8	16
124	Multiple Events of Fractures and Cardiovascular and Thromboembolic Disease Following Prostate Cancer Diagnosis: Results From the Population-Based PCBaSe Sweden. European Urology, 2012, 61, 690-700.	0.9	15
125	Baseline serum folate, vitamin B12 and the risk of prostate and breast cancer using data from the Swedish AMORIS cohort. Cancer Causes and Control, 2019, 30, 603-615.	0.8	15
126	Examination of potential novel biochemical factors in relation to prostate cancer incidence and mortality in UK Biobank. British Journal of Cancer, 2020, 123, 1808-1817.	2.9	15

#	Article	IF	Citations
127	Personalised biopsy schedules based on risk of Gleason upgrading for patients with lowâ€risk prostate cancer on active surveillance. BJU International, 2021, 127, 96-107.	1.3	15
128	Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review. European Urology Oncology, 2022, 5, 153-163.	2.6	15
129	The association between circulating IGF1, IGFBP3, and calcium: results from NHANES III. Endocrine Connections, 2015, 4, 187-195.	0.8	14
130	Real World Evidence: A Quantitative and Qualitative Glance at Participant Feedback from a Free-Response Survey Investigating Experiences of a Structured Exercise Intervention for Men with Prostate Cancer. BioMed Research International, 2017, 2017, 1-10.	0.9	14
131	Longitudinal study of body mass index, dyslipidemia, hyperglycemia, and hypertension in 60,000 men and women in Sweden and Austria. PLoS ONE, 2018, 13, e0197830.	1.1	14
132	Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study. Cancer Causes and Control, 2019, 30, 195-206.	0.8	14
133	Health-related quality of life overview after different curative treatment options in muscle-invasive bladder cancer: an umbrella review. Quality of Life Research, 2020, 29, 2887-2910.	1.5	14
134	Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study. Prostate Cancer and Prostatic Diseases, 2020, 23, 527-533.	2.0	14
135	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. Journal of the National Cancer Institute, 2022, 114, 979-987.	3.0	14
136	Guyâ€™s cancer cohort â€“ real world evidence for cancer pathways. BMC Cancer, 2020, 20, 187.	1.1	13
137	Association of Serum Immunoglobulin Levels with Solid Cancer: A Systematic Review and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 527-538.	1.1	13
138	COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients. Cancers, 2021, 13, 2479.	1.7	13
139	Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial. PLoS ONE, 2020, 15, e0243928.	1.1	13
140	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science, 2022, 35, 59-67.	0.2	13
141	Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. European Urology, 2022, 81, 503-514.	0.9	13
142	Antibodies as biomarkers for cancer risk: a systematic review. Clinical and Experimental Immunology, 2022, 209, 46-63.	1.1	13
143	Ability of a biomarker-based score to predict death from circulatory disease and cancer in NHANES III. BMC Public Health, 2012, 12, 895.	1.2	12
144	Are you now a good surgeon? T2 positive margin status as a quality outcome measure following radical prostatectomy. World Journal of Urology, 2017, 35, 35-43.	1.2	12

#	Article	IF	Citations
145	Diagnostic value of MRI-based PSA density in predicting transperineal sector-guided prostate biopsy outcomes. International Urology and Nephrology, 2017, 49, 1335-1342.	0.6	12
146	Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort. BMC Cancer, 2017, 17, 246.	1.1	12
147	Survival after radiotherapy versus radical cystectomy for primary muscleâ€invasive bladder cancer: A Swedish nationwide populationâ€based cohort study. Cancer Medicine, 2019, 8, 2196-2204.	1.3	12
148	Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer. European Urology, 2019, 75, 676-683.	0.9	12
149	Global cancer research in the era of COVID-19: a bibliometric analysis. Ecancermedicalscience, 2021, 15, 1264.	0.6	12
150	A meta-analysis of the efficacy of vascularised lymph node transfer in reducing limb volume and cellulitis episodes in patients with cancer treatment-related lymphoedema. European Journal of Cancer, 2021, 151, 233-244.	1.3	12
151	The Biology and Natural History of Prostate Cancer: A Short Introduction. Recent Results in Cancer Research, 2014, 202, 1-7.	1.8	11
152	How to model temporal changes in comorbidity for cancer patients using prospective cohort data. BMC Medical Informatics and Decision Making, 2015, 15, 96.	1.5	11
153	Associations of C-Reactive Protein, Granulocytes and Granulocyte-to-Lymphocyte Ratio with Mortality from Breast Cancer in Non-Institutionalized American Women. PLoS ONE, 2016, 11, e0157482.	1.1	11
154	Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden. Scandinavian Journal of Urology, 2020, 54, 20-26.	0.6	11
155	Harnessing the patient voice in prostate cancer research: Systematic review on the use of patientâ€reported outcomes in randomized controlled trials to support clinical decisionâ€making. Cancer Medicine, 2020, 9, 4039-4058.	1.3	11
156	Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21). Cancers, 2021, 13, 4690.	1.7	11
157	Global cancer research in the post-pandemic world. Lancet Oncology, The, 2021, 22, 1652-1654.	5.1	11
158	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. European Journal of Cancer, 2022, 170, 10-16.	1.3	11
159	A comparison of the left thoracoabdominal and Ivorâ€"Lewis esophagectomy. Ecological Management and Restoration, 2018, 31, .	0.2	10
160	Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review. BMC Urology, 2019, 19, 86.	0.6	10
161	A mediation analysis to explain socioâ€economic differences in bladder cancer survival. Cancer Medicine, 2020, 9, 7477-7487.	1.3	10
162	Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study. BMC Cancer, 2020, 20, 551.	1.1	10

#	Article	IF	Citations
163	Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer. Translational Andrology and Urology, 2021, 10, 2728-2736.	0.6	10
164	ReIMAGINE Prostate Cancer Screening Study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI. BMJ Open, 2021, 11, e048144.	0.8	10
165	Serum Total Bilirubin and Risk of Cancer: A Swedish Cohort Study and Meta-Analysis. Cancers, 2021, 13, 5540.	1.7	10
166	Interpretation of conventional survival analysis and competingâ€risk analysis: an example of hypertension and prostate cancer. BJU International, 2016, 118, 850-852.	1.3	9
167	A latent class model for competing risks. Statistics in Medicine, 2017, 36, 2100-2119.	0.8	9
168	Prostate Cancer Radiation Therapy and Risk of Thromboembolic Events. International Journal of Radiation Oncology Biology Physics, 2017, 97, 1026-1031.	0.4	9
169	Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort. Breast Cancer Research, 2017, 19, 22.	2.2	9
170	Patients' perspectives on opt-out consent for observational research: systematic review and focus group. British Journal of Nursing, 2018, 27, 1321-1329.	0.3	9
171	H eterogeneity in risk of prostate cancer: A S wedish populationâ€based cohort study of competing risks and T ype 2 diabetes mellitus. International Journal of Cancer, 2018, 143, 1868-1875.	2.3	9
172	Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer: a population-based case-control study. BMC Cancer, 2019, 19, 612.	1.1	9
173	A randomized trial of exercise on quality of life in men with metastatic prostate cancer: The ExPeCT Trial.. Journal of Clinical Oncology, 2019, 37, 97-97.	0.8	9
174	Association between COVID-19 burden and delays to diagnosis and treatment of cancer patients in England. Journal of Cancer Policy, 2022, 31, 100316.	0.6	9
175	Optimising magnetic sentinel lymph node biopsy in an in vivo porcine model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 993-1002.	1.7	8
176	Research engagement among black men with prostate cancer. Ecancermedicalscience, 2016, 10, 695.	0.6	8
177	Raised preoperative international normalised ratio (INR) identifies patients at high risk of perioperative death after simultaneous renal and cardiac surgery for tumours involving the periâ€diaphragmatic inferior vena cava and right atrium. BJU International, 2017, 119, 424-429.	1.3	8
178	Kingâ€™s Health Partnersâ€™ Prostate Cancer Biobank (KHP PCaBB). BMC Cancer, 2017, 17, 784.	1.1	8
179	Does a prostate cancer diagnosis affect management of pre-existing diabetes? Results from PCBaSe Sweden: a nationwide cohort study. BMJ Open, 2018, 8, e020787.	0.8	8
180	Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer. Oncotarget, 2018, 9, 12812-12824.	0.8	8

#	Article	IF	Citations
181	Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival. Scandinavian Journal of Urology, 2019, 53, 206-212.	0.6	8
182	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology, 2019, 2, 333-336.	2.6	8
183	A Single Educational Seminar Increases Confidence and Decreases Dropout from Active Surveillance by 5 Years After Diagnosis of Prostate Cancer. European Urology Oncology, 2019, 2, 464-470.	2.6	8
184	One Piece of the Jigsaw for the Cancer Recovery Strategy: Prevalence of COVID-19 in Patients With Cancer. Cancer Control, 2020, 27, 107327482095084.	0.7	8
185	Supportive care needs and utilization of bladder cancer patients undergoing radical cystectomy: A longitudinal study. Psycho-Oncology, 2022, 31, 219-226.	1.0	8
186	Providing a Framework for Meaningful Patient Involvement in Clinical Practice Guideline Development and Implementation. European Urology Focus, 2021, 7, 947-950.	1.6	8
187	An assessment of the use of patient reported outcome measurements (PROMs) in cancers of the pelvic abdominal cavity: identifying oncologic benefit and an evidence-practice gap in routine clinical practice. Health and Quality of Life Outcomes, 2021, 19, 20.	1.0	8
188	Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma â€“ A comparison of the FLOT and â€˜MAGICâ€™ regimens. European Journal of Cancer, 2022, 163, 180-188.	1.3	8
189	Population-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males. BMC Medical Informatics and Decision Making, 2022, 22, 35.	1.5	8
190	Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study. Ecancermedicalscience, 2015, 9, 555.	0.6	7
191	Serial transperineal sector prostate biopsies: impact on long-term erectile dysfunction. Ecancermedicalscience, 2016, 10, 643.	0.6	7
192	Graham Roberts Study protocol: first â€˜trials within cohort studyâ€™ for bladder cancer. BMJ Open, 2019, 9, e029468.	0.8	7
193	Exploring a role for fatty acid synthase in prostate cancer cell migration. Small GTPases, 2020, 12, 1-8.	0.7	7
194	Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study. Frontiers in Oncology, 2020, 10, 263.	1.3	7
195	Gender Differences in Concerns About Participating in Cancer Research During the COVID-19 Pandemic. Cancer Control, 2021, 28, 107327482198931.	0.7	7
196	Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. Acta OncolÃ³gica, 2021, 60, 459-465.	0.8	7
197	Survival Outcomes in Invasive Lobular Carcinoma Compared to Oestrogen Receptor-Positive Invasive Ductal Carcinoma. Cancers, 2021, 13, 3036.	1.7	7
198	Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study. BMC Immunology, 2021, 22, 61.	0.9	7

#	Article	IF	Citations
199	Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum. Oncotarget, 2018, 9, 774-782.	0.8	7
200	Impact of the COVID-19 Pandemic on Cancer Researchers in 2020: A Qualitative Study of Events to Inform Mitigation Strategies. Frontiers in Public Health, 2021, 9, 741223.	1.3	7
201	Confirmatory biopsy for the assessment of prostate cancer in men considering active surveillance: reference centre experience. Ecancermedicalscience, 2016, 10, 633.	0.6	6
202	Laparoscopic radical prostatectomy outcome data: how should surgeonâ€™s performance be reported? A retrospective learning curve analysis of two surgeons. Ecancermedicalscience, 2016, 10, 651.	0.6	6
203	The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial. Trials, 2017, 18, 456.	0.7	6
204	Serum biomarkers to predict risk of testicular and penile cancer in AMORIS. Ecancermedicalscience, 2017, 11, 762.	0.6	6
205	Overall survival, diseaseâ€specific survival and local recurrence outcomes in patients with muscleâ€invasive bladder cancer treated with external beam radiotherapy and brachytherapy: a systematic review. BJU International, 2020, 125, 780-791.	1.3	6
206	Systematic review of the association between socioeconomic status and bladder cancer survival with hospital type, comorbidities, and treatment delay as mediators. BJUI Compass, 2021, 2, 140-158.	0.7	6
207	Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative. Journal of Urology, 2021, 206, 62-68.	0.2	6
208	The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. European Urology Focus, 2021, 7, 943-946.	1.6	6
209	A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0. PLoS ONE, 2018, 13, e0195690.	1.1	6
210	Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire. Journal of Cancer Survivorship, 2023, 17, 1111-1130.	1.5	6
211	An investigation into the relationship between statins and cancer using population-based data. BJU International, 2015, 116, 681-683.	1.3	5
212	Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival?. BMC Cancer, 2018, 18, 1169.	1.1	5
213	Scoping review protocol: is there a role for physical activity interventions in the treatment pathway of bladder cancer?. BMJ Open, 2019, 9, e033518.	0.8	5
214	Serum IgG Is Associated With Risk of Melanoma in the Swedish AMORIS Study. Frontiers in Oncology, 2019, 9, 1095.	1.3	5
215	The experience of UK patients with bladder cancer during the COVIDâ€19 pandemic: a surveyâ€based snapshot. BJU International, 2021, 127, 179-181.	1.3	5
216	Scoping review protocol: bladder cancer in Nigeria: what are the gaps in clinical care and research?. BMJ Open, 2021, 11, e041894.	0.8	5

#	Article	IF	Citations
217	Pancreatic Cancer Exposome Profile to Aid Early Detection and Inform Prevention Strategies. Journal of Clinical Medicine, 2021, 10, 1665.	1.0	5
218	Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging. European Urology Focus, 2021, 7, 503-505.	1.6	5
219	Erectile Function Following Surgery for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. European Urology, 2021, 80, 174-187.	0.9	5
220	Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer. Journal of Patient-Reported Outcomes, 2021, 5, 96.	0.9	5
221	The Current Evidence for Factors that Influence Treatment Decision Making in Localized Kidney Cancer: A Mixed Methods Systematic Review. Journal of Urology, 2021, 206, 827-839.	0.2	5
222	The need for supportive mental wellbeing interventions in bladder cancer patients: A systematic review of the literature. PLoS ONE, 2021, 16, e0243136.	1.1	5
223	Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer. Scandinavian Journal of Urology, 2022, 56, 27-33.	0.6	5
224	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110534.	1.4	5
225	Association of serum calcium with serum sex steroid hormones in men in NHANES III. Aging Male, 2013, 16, 151-158.	0.9	4
226	Atopy and prostate cancer: Is there a link between circulating levels of IgE and PSA in humans?. Cancer Immunology, Immunotherapy, 2017, 66, 1557-1562.	2.0	4
227	Association between type 2 diabetes, curative treatment and survival in men with intermediateâ€•and highâ€•risk localized prostate cancer. BJU International, 2018, 121, 209-216.	1.3	4
228	Metabolic profiles to predict long-term cancer and mortality: the use of latent class analysis. BMC Molecular and Cell Biology, 2019, 20, 28.	1.0	4
229	Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. Cancer Epidemiology, 2019, 62, 101584.	0.8	4
230	Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. Acta OncolÃ³gica, 2019, 58, 110-118.	0.8	4
231	Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study. Frontiers in Oncology, 2020, 10, 571838.	1.3	4
232	Development of a preâ€•and postoperative physical activity promotion program integrated in the electronic health system of patients with bladder cancer (The POPEYE study): An intervention mapping approach. European Journal of Cancer Care, 2021, 30, e13363.	0.7	4
233	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110422.	1.4	4
234	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. BMJ Open, 2021, 11, e040531.	0.8	4

#	Article	IF	Citations
235	Is there a role for physical activity interventions in the treatment pathway of bladder cancer? A scoping review of the literature. BMJ Open Sport and Exercise Medicine, 2021, 7, e000951.	1.4	4
236	Using the Movember Foundationâ€™s GAP3 cohort to measure the effect of active surveillance on patient-reported urinary and sexual functionâ€”a retrospective study in low-risk prostate cancer patients. Translational Andrology and Urology, 2021, 10, 2719-2727.	0.6	4
237	Supportive Roles of the Health Care Team Throughout the Illness Trajectory of Bladder Cancer Patients Undergoing Radical Cystectomy: A Qualitative Study Exploring the Patientsâ€™ Perspectives. Seminars in Oncology Nursing, 2021, 37, 151226.	0.7	4
238	The impact of hospital attendance on COVID-19 infection in cancer patients: an assessment of data from Guy's Cancer. Future Oncology, 2022, 18, 1211-1218.	1.1	4
239	MRI-based nomogram for the prediction of prostate cancer diagnosis: A multi-centre validated patientâ€“physician decision tool. Journal of Clinical Urology, 0, , 205141582110659.	0.1	4
240	COVID-19 vaccination in patients with cancer, a rapid review. Ecancermedicalscience, 2022, 16, 1355.	0.6	4
241	An exploration of wellbeing in men diagnosed with prostate cancer undergoing active surveillance: a qualitative study. Supportive Care in Cancer, 2022, 30, 5459-5468.	1.0	4
242	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review. BMJ Open, 2022, 12, e058267.	0.8	4
243	Drugs for metabolic conditions and prostate cancer death in men on Gn<scp>RH</scp> agonists. BJU International, 2018, 121, 260-267.	1.3	3
244	Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort. BMC Cancer, 2018, 18, 205.	1.1	3
245	How to measure temporal changes in care pathways for chronic diseases using health care registry data. BMC Medical Informatics and Decision Making, 2019, 19, 103.	1.5	3
246	Realâ€world insights into risk of developing cardiovascular disease following Gn<scp>RH</scp> agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases. Fundamental and Clinical Pharmacology, 2019, 33, 479-499.	1.0	3
247	Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus. BJS Open, 2019, 3, 767-776.	0.7	3
248	Selenium and Sex Steroid Hormones in a U.S. Nationally Representative Sample of Men: A Role for the Link between Selenium and Estradiol in Prostate Carcinogenesis?. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 578-583.	1.1	3
249	Negative first followâ€up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment. BJU International, 2021, 128, 72-78.	1.3	3
250	Effect of a brief physical activity-based presentation by a former patient for men treated with radical prostatectomy for prostate cancer: a mixed methods pilot study. Supportive Care in Cancer, 2021, 29, 145-154.	1.0	3
251	Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins. Acta OncolÃ³gica, 2021, 60, 672-680.	0.8	3
252	Outcomes of head and neck cancer management from two cancer centres in Southern and Northern Europe during the first wave of COVID-19. Tumori, 2021, , 030089162110079.	0.6	3

#	Article	IF	Citations
253	The importance of patient and public involvement in cancer research: time to create a new job profile. Future Oncology, 2021, 17, 3667-3670.	1.1	3
254	Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database. European Urology Open Science, 2021, 34, 47-54.	0.2	3
255	ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement. Research Involvement and Engagement, 2021, 7, 81.	1.1	3
256	Hormonal patterns in men with prediabetes and diabetes in NHANES III: possible links with prostate cancer. Cancer Causes and Control, 2022, 33, 429-440.	0.8	3
257	Impact of the COVIDâ€19 pandemic on urological cancers: The surgical experience of two cancer hubs in London and Milan. BJUI Compass, 0, , .	0.7	3
258	Evaluating the performance of temporal pattern discovery: new application using statins and rhabdomyolysis in OMOP databases. BMC Medical Informatics and Decision Making, 2022, 22, 31.	1.5	3
259	Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin. British Journal of Surgery, 2020, 107, 1801-1810.	0.1	3
260	The Association of Milk and Dairy Consumption and Calcium Intake With the Risk and Severity of Prostate Cancer. Current Nutrition Reports, 2015, 4, 66-71.	2.1	2
261	Brief behavioural intervention, delivered as standard care, to support physical activity engagement in men with prostate cancer: a pilot study protocol. BMJ Open Sport and Exercise Medicine, 2018, 4, e000469.	1.4	2
262	The burden of urological cancers in lowâ€•and middleâ€•income countries. BJU International, 2019, 123, 557-557.	1.3	2
263	Editorial: Bladder Cancer â€“ A Cinderella Cancer: Advances and Remaining Research Questions. Frontiers in Oncology, 2020, 10, 1749.	1.3	2
264	Feasibility study to identify women of childbearing age at risk of pregnancy not using any contraception in The Health Improvement Network (THIN) database. BMC Medical Informatics and Decision Making, 2020, 20, 164.	1.5	2
265	How does COVIDâ€19 impact treatment decisionâ€making for clinicians in localised kidney cancer. BJUI Compass, 2021, 2, 11-12.	0.7	2
266	Guyâ€™s and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database. BMC Cancer, 2021, 21, 573.	1.1	2
267	Designing a Pragmatic Intervention to Help Improve the Bladder Cancer Patient Experience. Inquiry (United States), 2021, 58, 004695802110302.	0.5	2
268	The effect of a structured exercise intervention on CTCs and platelet cloaking in patients with metastatic prostate cancer.. Journal of Clinical Oncology, 2019, 37, 243-243.	0.8	2
269	Predicting response to neoadjuvant chemotherapy in patients with oesophageal adenocarcinoma. Acta OncolÃ³gica, 2021, 60, 1629-1636.	0.8	2
270	The ReIMAGINE Multimodal Warehouse: Using Artificial Intelligence for Accurate Risk Stratification of Prostate Cancer. Frontiers in Artificial Intelligence, 2021, 4, 769582.	2.0	2

#	Article	IF	Citations
271	The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guyâ€™s Cancer Centre. Cancers, 2022, 14, 266.	1.7	2
272	C-CRES: COVID-19 and cancer research engagement study.. Journal of Clinical Oncology, 2020, 38, 182-182.	0.8	2
273	Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate, 2022, 82, 876-879.	1.2	2
274	Qualitative Analysis of Interviews and Focus Groups Exploring Factors Contributing to Adherence to GnRH Agonists in Men with Prostate Cancer. Seminars in Oncology Nursing, 2022, 38, 151236.	0.7	2
275	Radical cancer treatment is safe during COVID-19: the real-world experience of a large London-based Comprehensive Cancer Centre during the first wave. British Journal of Cancer, 0, , .	2.9	2
276	The risk of cardiovascular disease following GnRH agonists versus antagonists: Real-world evidence from four European countries. European Urology Supplements, 2018, 17, e1850.	0.1	1
277	Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol 2019;76:260â€“1. European Urology, 2019, 76, e45-e46.	0.9	1
278	PIONEERâ€™s systematic review of outcomes in RCTs of men with non-metastatic castration resistant prostate cancer: Is there a need for a core outcome set?. European Urology Open Science, 2020, 19, e1795.	0.2	1
279	Presentation, follow-up, and outcomes among African/Afro-Caribbean men on active surveillance for prostate cancer: experiences of a high-volume UK centre. Prostate Cancer and Prostatic Diseases, 2021, 24, 549-557.	2.0	1
280	Factors that influence patientsâ€™ views on treatment decision-making in localised kidney cancer. Translational Andrology and Urology, 2021, 10, 2824-2827.	0.6	1
281	The need for research methodology to improve acceptability of long-term surveillance for cancer. Translational Andrology and Urology, 2021, 10, 2820-2823.	0.6	1
282	Is there an anti-androgen withdrawal effect with enzalutamide?. Journal of Clinical Oncology, 2014, 32, 200-200.	0.8	1
283	Your next clinical cancer research project: preparation in a. Ecancermedicalscience, 2017, 11, ed64.	0.6	1
284	Phenotyping Gamma Delta T cells in Bladder Cancer. Frontiers in Oncology, 0, 9, .	1.3	1
285	Is there a role for physical activity when treating patients with cancer with immune checkpoint inhibitors? Protocol for a scoping review. BMJ Open, 2021, 11, e046052.	0.8	1
286	â€œSomething Good Has to Come Out of the Horrorâ€¦ A Qualitative Examination of Cancer Survivors' Attitudes Towards Participation in Research During the First Year of the COVID-19 Pandemic. Frontiers in Public Health, 2021, 9, 741188.	1.3	1
287	Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study. BMC Cancer, 2021, 21, 1259.	1.1	1
288	Developing a consensus statement for psychosocial support in active surveillance for prostate cancer. BJUI Compass, 2023, 4, 104-113.	0.7	1

#	Article	IF	Citations
289	The experience of UK patients with bladder cancer during the second wave of the COVIDâ€19 pandemic. BJUI Compass, 0, , .	0.7	1
290	Clinical assessment of the Omicron outbreak in Europe and trends in morbidity and mortality from COVID-19 and cancer.. Journal of Clinical Oncology, 2022, 40, e18673-e18673.	0.8	1
291	Re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol 2016;70:56â€“61. European Urology, 2017, 71, e61-e62.	0.9	0
292	Human development and its impact on genitourinary cancers. BJU International, 2017, 120, 747-748.	1.3	0
293	Occupational exposure and risk of testicular cancer: what can an ecological study in the Nordic countries tell us?. BJU International, 2018, 122, 351-351.	1.3	0
294	Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?. BMC Urology, 2019, 19, 73.	0.6	0
295	Cohort profile: Kingâ€™s Health Partners bladder cancer biobank. BMC Cancer, 2020, 20, 920.	1.1	0
296	A first step towards a global nomogram to predict disease progression for men on active surveillance. Translational Andrology and Urology, 2021, 10, 1102-1109.	0.6	0
297	Expectant management in genitourinary malignancies (prostate, bladder, kidney). Translational Andrology and Urology, 2021, 10, 2715-2718.	0.6	0
298	646 PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH OESOPHAGEAL ADENOCARCINOMA. Ecological Management and Restoration, 2021, 34, .	0.2	0
299	Reply by Authors. Journal of Urology, 2021, 206, 839-839.	0.2	0
300	Role of serum lipids and glucose as biomarkers of prostate cancer severity.. Journal of Clinical Oncology, 2014, 32, 5080-5080.	0.8	0
301	Determinants of non-adherence to adjuvant endocrine treatment in early stage breast cancer patients: A Swedish population-based registry linkage study.. Journal of Clinical Oncology, 2016, 34, 535-535.	0.8	0
302	Spezifische Todesursachen von Patienten mit nicht-metastasierenden Prostatakrebs. Gesundheitswesen, 2017, 79, .	0.8	0
303	Repurposing tin mesoporphyrin as a novel immune checkpoint therapy in the treatment of cancer: A preclinical evaluation.. Journal of Clinical Oncology, 2018, 36, e15129-e15129.	0.8	0
304	Abstract A059: Lifestyle and health-related quality of life in men with metastatic prostate cancer. , 2018, , .		0
305	Abstract A057: Examining the link between obesity, inflammation, and exercise in patients with metastatic prostate cancerâ€”An interim analysis from the ExPeCT trial. , 2018, , .		0
306	Is brachytherapy a viable treatment option for muscle-invasive bladder cancer?. Frontiers in Oncology, 0, 9, .	1.3	0

#	Article	IF	Citations
307	A pilot study to evaluate patient reported outcome measures of bladder cancer patients undergoing radical cystectomy at Guyâ€™s and St Thomasâ€™ NHS Foundation Trust.. Frontiers in Oncology, 0, 9, .	1.3	0
308	Neutrophil to lymphocyte ratio (NLR) as a predictor of outcomes in patients with urothelial carcinoma (UC) treated with immune checkpoint inhibitors (ICI). Frontiers in Oncology, 0, 9, .	1.3	0
309	Clinical outcomes of patients with squamous cell bladder cancer versus urothelial carcinoma with squamous differentiation after radical treatment. Frontiers in Oncology, 0, 9, .	1.3	0
310	Cohort Profile: Kingâ€™s Health Partners Bladder Cancer Biobank (KHP BCaBB). Frontiers in Oncology, 0, 9, .	1.3	0
311	The role of iron infusion in post-operative outcomes following radical cystectomy. Frontiers in Oncology, 0, 9, .	1.3	0
312	Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. Frontiers in Oncology, 0, 9, .	1.3	0
313	MP22-11â€ƒCHANGES IN COMORBIDITY AFTER TREATMENT WITH GONADOTROPHIN RELEASING AGONISTS VERSUS ANTI-ANDROGEN MONOTHERAPY IN MEN WITH ADVANCED NON-METASTATIC PROSTATE CANCER. Journal of Urology, 2019, 201, .	0.2	0
314	MP48-07â€ƒTHIRTY-YEAR NATIONWIDE POPULATION-BASED FOLLOW-UP OF MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER: WHO BENEFITS THE MOST? A STATE-TRANSITION ANALYSIS. Journal of Urology, 2019, 201, .	0.2	0
315	MP48-18â€ƒIS PSA â€˜SCREENINGâ€™ BEHAVIOUR ASSOCIATED WITH UPTAKE OF ACTIVE SURVEILLANCE IN MEN WITH LOW RISK PROSTATE CANCER?. Journal of Urology, 2019, 201, .	0.2	0
316	LBA01-05â€ƒSIMULATION IN UROLOGICAL TRAINING AND EDUCATION (SIMULATE): AN INTERNATIONAL RANDOMISED CONTROLLED CLINICAL AND EDUCATIONAL TRIAL TO DETERMINE THE EFFECT OF SIMULATION-BASED SURGICAL TRAINING. Journal of Urology, 2020, 203, .	0.2	0
317	PD62-01â€ƒA FIRST STEP TOWARDS A GLOBAL NOMOGRAM TO PREDICT DISEASE PROGRESSION FOR MEN ON ACTIVE SURVEILLANCE. Journal of Urology, 2020, 203, e1285.	0.2	0
318	PD62-11â€ƒPATIENT-REPORTED ERECTILE AND URINARY FUNCTION AFTER REPEAT BIOPSIES IN MEN ON ACTIVE SURVEILLANCE. RESULTS OF THE MOVEMBER FOUNDATIONâ€™S GAP3 COHORT. Journal of Urology, 2020, 203, .	0.2	0
319	Independent Prognostic Value of Flow Cytometry (FCM) in Myelodysplastic Syndromes (MDS) - Composition of a Prognostic FCM-Score for Overall Survival. Blood, 2021, 138, 2603-2603.	0.6	0
320	The success of the Rapid Diagnostic Clinic (RDC) detecting new cancers in patients with non-localizing symptoms.. Journal of Clinical Oncology, 2020, 38, 303-303.	0.8	0
321	Disparities in COVID-19 severity and risk of death in cancer patients: Experiences from a U.K. cancer center.. Journal of Clinical Oncology, 2020, 38, 285-285.	0.8	0
322	Scoping review: bladder cancer in Nigeria â€“ what are the gaps in clinical care and research?. BMJ Open, 2022, 12, e049241.	0.8	0
323	Cancer staff in an NHS cancer center: infections, vaccination, stress and well-being support during the COVID-19 pandemic. Future Oncology, 2022, , .	1.1	0
324	Safe provision of systemic anti-cancer treatment for urological cancer patients during COVID-19: a tertiary centre experience in the first wave of COVID-19. BMC Urology, 2022, 22, 71.	0.6	0

#	Article	IF	Citations
325	Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform. Journal of Personalized Medicine, 2022, 12, 751.	1.1	0